| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K A Stockwell, D K A Scheller, L A Smith, S Rose, M M Iravani, M J Jackson, P Jenne. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Experimental neurology. vol 221. issue 1. 2010-02-16. PMID:19833125. |
in addition, while the continuous delivery of rotigotine prevented the expression of dyskinesia, the previously demonstrated ability of dopamine agonists to prime for dyskinesia could not be avoided. |
2010-02-16 |
2023-08-12 |
Not clear |
| N Yamamoto, J-J Soghomonia. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. vol 163. issue 4. 2010-02-12. PMID:19660528. |
the present study examined the effect of a subchronic systemic administration of the glutamate metabotropic mglur5 receptor antagonist mpep on l-dopa-induced dyskinesias and striatal gene expression in adult rats with a unilateral 6-ohda lesion of dopamine neurons. |
2010-02-12 |
2023-08-12 |
rat |
| Kerstin Buck, Patrizia Voehringer, Boris Ferge. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of neurochemistry. vol 112. issue 2. 2010-02-05. PMID:19895663. |
the alpha(2) adrenoceptor antagonist idazoxan alleviates l-dopa-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. |
2010-02-05 |
2023-08-12 |
rat |
| Kerstin Buck, Patrizia Voehringer, Boris Ferge. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of neurochemistry. vol 112. issue 2. 2010-02-05. PMID:19895663. |
here, we investigate effects of the a2 adrenoceptor antagonist idazoxan on l-dopa-induced dyskinesia as well as on alterations of extracellular l-dopa and dopamine (da) levels in the striatum in dyskinetic rats. |
2010-02-05 |
2023-08-12 |
rat |
| Ken Ikeda, Satoru Yoshikawa, Takahiro Kurokawa, Natsumi Yuzawa, Kaoru Nakao, Hidenori Mochizuk. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. European journal of pharmacology. vol 620. issue 1-3. 2009-12-31. PMID:19686730. |
in vivo microdialysis study, trk-820 (30 microg/kg, s.c.) significantly inhibited l-dopa-derived extracellular dopamine content in the 6-ohda-treated striatum in dyskinesia rats, but not in hemi-parkinsonian rats. |
2009-12-31 |
2023-08-12 |
rat |
| Ken Ikeda, Satoru Yoshikawa, Takahiro Kurokawa, Natsumi Yuzawa, Kaoru Nakao, Hidenori Mochizuk. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. European journal of pharmacology. vol 620. issue 1-3. 2009-12-31. PMID:19686730. |
these results have suggested that trk-820 ameliorates l-dopa-induced dyskinesia with a moderate anti-parkinsonian effect by inhibiting l-dopa-induced excessive dopamine release through kappa opioid receptors only in dyskinesia rats; therefore, trk-820 is expected to become a useful agent for the treatment of l-dopa-induced dyskinesia. |
2009-12-31 |
2023-08-12 |
rat |
| C Warren Olanow, Jeffrey H Kordower, Anthony E Lang, Jose A Obes. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Annals of neurology. vol 66. issue 5. 2009-12-21. PMID:19938101. |
however, all double-blind, sham-controlled, studies have failed to meet their primary endpoints, and transplantation of dopamine cells derived from the fetal mesencephalon is associated with a potentially disabling form of dyskinesia that persists even after withdrawal of levodopa (off-medication dyskinesia). |
2009-12-21 |
2023-08-12 |
Not clear |
| Sanja Darmopil, Ana B Martín, Irene Ruiz De Diego, Sara Ares, Rosario Moratall. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biological psychiatry. vol 66. issue 6. 2009-11-09. PMID:19520364. |
genetic inactivation of dopamine d1 but not d2 receptors inhibits l-dopa-induced dyskinesia and histone activation. |
2009-11-09 |
2023-08-12 |
mouse |
| Sanja Darmopil, Ana B Martín, Irene Ruiz De Diego, Sara Ares, Rosario Moratall. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biological psychiatry. vol 66. issue 6. 2009-11-09. PMID:19520364. |
pharmacologic studies have implicated dopamine d1-like receptors in the development of dopamine precursor molecule 3,4-dihydroxyphenyl-l-alanine (l-dopa)-induced dyskinesias and associated molecular changes in hemiparkinsonian mice. |
2009-11-09 |
2023-08-12 |
mouse |
| K A Stockwell, D Scheller, S Rose, M J Jackson, K Tayarani-Binazir, M M Iravani, L A Smith, C W Olanow, P Jenne. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Experimental neurology. vol 219. issue 2. 2009-09-29. PMID:19619533. |
however, continuous rotigotine administration did not prevent l-dopa from inducing dyskinesia suggesting that l-dopa may induce dyskinesia by mechanisms different from dopamine agonist drugs. |
2009-09-29 |
2023-08-12 |
monkey |
| Naomi P Visanji, Susan H Fox, Tom Johnston, Gabriela Reyes, Mark J Millan, Jonathan M Brotchi. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiology of disease. vol 35. issue 2. 2009-09-21. PMID:19118628. |
dopamine d3 receptor stimulation underlies the development of l-dopa-induced dyskinesia in animal models of parkinson's disease. |
2009-09-21 |
2023-08-12 |
rat |
| Lauren C Seeberger, Robert A Hause. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert review of neurotherapeutics. vol 9. issue 7. 2009-09-21. PMID:19589043. |
mounting evidence indicates the short half-life of levodopa and resultant pulsatile stimulation of striatal dopamine receptors leads to wearing off, motor fluctuations and dyskinesias. |
2009-09-21 |
2023-08-12 |
Not clear |
| Lauren C Seeberger, Robert A Hause. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert review of neurotherapeutics. vol 9. issue 7. 2009-09-21. PMID:19589043. |
longer acting dopaminergic agents, such as dopamine agonists, are less likely to cause motor fluctuations and dyskinesias but are not as efficacious for control of motor symptoms. |
2009-09-21 |
2023-08-12 |
Not clear |
| Gianluigi Lunardi, Salvatore Galati, Domenicantonio Tropepi, Vincenzo Moschella, Livia Brusa, Mariangela Pierantozzi, Alessandro Stefani, Silvia Rossi, Francesco Fornai, Ernesto Fedele, Paolo Stanzione, Atticus H Hainsworth, Antonio Pisan. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism & related disorders. vol 15. issue 5. 2009-09-16. PMID:19010710. |
correlation between changes in csf dopamine turnover and development of dyskinesia in parkinson's disease. |
2009-09-16 |
2023-08-12 |
Not clear |
| Gianluigi Lunardi, Salvatore Galati, Domenicantonio Tropepi, Vincenzo Moschella, Livia Brusa, Mariangela Pierantozzi, Alessandro Stefani, Silvia Rossi, Francesco Fornai, Ernesto Fedele, Paolo Stanzione, Atticus H Hainsworth, Antonio Pisan. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism & related disorders. vol 15. issue 5. 2009-09-16. PMID:19010710. |
to assess possible differences in dopamine metabolism that could parallel disease progression in parkinson's disease (pd), we measured dopamine (da) and its metabolites in the cerebrospinal fluid (csf) in pd patients at different stages of disease: de novo (den), advanced not showing dyskinesias (adv), and advanced with dyskinesias (dys). |
2009-09-16 |
2023-08-12 |
Not clear |
| Emma Louise Lane, Patrik Brundin, M Angela Cenc. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of disease. vol 35. issue 1. 2009-09-14. PMID:19361557. |
these data point to a major role for dopamine receptors, and to a modulatory role for 5-ht(1a) receptors, in post-grafting dyskinesias. |
2009-09-14 |
2023-08-12 |
rat |
| Gurutz Linazasor. Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity. Clinical neuropharmacology. vol 32. issue 1. 2009-09-02. PMID:18978500. |
dopamine dysregulation syndrome and levodopa-induced dyskinesias in parkinson disease: common consequences of anomalous forms of neural plasticity. |
2009-09-02 |
2023-08-12 |
Not clear |
| Anti Kalda, Laura Herm, Ago Rinken, Alexander Zharkovsky, Jiang-Fan Che. Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice. Behavioural brain research. vol 202. issue 2. 2009-08-19. PMID:19463706. |
while dopamine replacement remains the standard pharmacotherapy for parkinson's disease, chronic l-dopa treatment is associated with development of debilitating motor fluctuations such as l-dopa-induced dyskinesia (lid). |
2009-08-19 |
2023-08-12 |
mouse |
| Fabio Blandini, Eleonora Bazzini, Franca Marino, Federica Saporiti, Marie-Therese Armentero, Claudio Pacchetti, Roberta Zangaglia, Emilia Martignoni, Sergio Lecchini, Giuseppe Nappi, Marco Cosentin. Calcium homeostasis is dysregulated in parkinsonian patients with L-DOPA-induced dyskinesias. Clinical neuropharmacology. vol 32. issue 3. 2009-08-10. PMID:18978486. |
l-dopa-induced dyskinesias are likely due to changes in the signal transduction pathways, at the striatal level, related to pulsatile stimulation of dopamine receptors. |
2009-08-10 |
2023-08-12 |
Not clear |
| C Marin, E Aguilar, M C Rodríguez-Oroz, G D Bartoszyk, J A Obes. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology. vol 204. issue 2. 2009-08-05. PMID:19159919. |
it is thus conceivable that a modulation of synaptic dopamine (da) levels induced by the inhibition of serotonin (5-ht) release, as a consequence of 5-ht(1a) agonists administration, might alleviate dyskinesias. |
2009-08-05 |
2023-08-12 |
rat |